Compare HIW & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | CRNX |
|---|---|---|
| Founded | 1978 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1995 | 2018 |
| Metric | HIW | CRNX |
|---|---|---|
| Price | $31.22 | $84.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $27.57 | ★ $76.75 |
| AVG Volume (30 Days) | 906.2K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.43% | N/A |
| EPS Growth | ★ 54.26 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $806,112,000.00 | $1,039,000.00 |
| Revenue This Year | $6.03 | $720.10 |
| Revenue Next Year | $3.58 | $184.67 |
| P/E Ratio | $108.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.45 | $32.30 |
| 52 Week High | $35.44 | $85.01 |
| Indicator | HIW | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 89.88 |
| Support Level | $31.01 | $83.47 |
| Resistance Level | $32.18 | N/A |
| Average True Range (ATR) | 0.55 | 0.12 |
| MACD | -0.05 | -0.86 |
| Stochastic Oscillator | 73.14 | 93.85 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.